Medication info

Megalivanron Injection (Sodium Ivanthronate Dihydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
LNC Bio Co., Ltd.
Appearance
A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use injection needle attached.
Packaging
3mL × 1 vial
Approval status
Active

MFDS item code 202000216 · Notified 2020.01.14 · Insurance code 060500891

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer it as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. Since clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this drug is not recommended. Elderly No dose adjustment is necessary.
Child administration
Efficacy and safety in children 18 years of age or younger have not been studied.

Ingredients

Manufacturer
LNC Bio Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis in postmenopausal women. Osteoporosis is a condition where the strength of bones decreases, leading to an increased risk of fractures, particularly common in women after menopause. This drug helps prevent bone loss and maintain bone health, thereby reducing the risk of fractures. Therefore, it is effective for the prevention and treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Inject 3mg intravenously over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer it as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. Since clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this drug is not recommended. Elderly No dose adjustment is necessary.

Child administration

Efficacy and safety in children 18 years of age or younger have not been studied.

Precautions

This drug must be administered intravenously, and great care must be taken when administering it intra-arterially or perivascularly, as it may cause tissue damage. This medication should not be used in patients who are allergic to this drug or any of its components, or in patients with untreated hypocalcemia. During the use of this drug, gastrointestinal symptoms such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, or constipation may occur. Additionally, cases of muscle pain, joint pain, headache, rash, fatigue, and flu-like symptoms have also been reported. Particularly, when this medication is given as an intravenous injection, transient flu-like symptoms may occur during the initial administration, typically mild to moderate in severity and self-resolving without treatment. Prior to administration, it is important to check for hypocalcemia or any bone and mineral metabolism disorders, and if necessary, ensure adequate intake of calcium and vitamin D. In patients undergoing dental treatment or with poor oral hygiene, there is a risk of jaw osteonecrosis, therefore it is advisable to undergo a dental check-up before administration. It is safe to avoid excessive dental treatments during administration. Moreover, in patients who have used this drug for a long time, atypical fractures may occur in the femur or other bones; therefore, if pain occurs in the thigh or groin, consult a physician immediately. This drug is excreted through the kidneys, so patients with impaired renal function should undergo regular renal function tests and follow the physician's instructions for administration. Safety during pregnancy or breastfeeding has not been established, so it is advisable to avoid use. In cases of overdose, hypocalcemia, hypophosphatemia, and hypomagnesemia may occur, immediate medical attention is necessary, and renal and liver function should be monitored closely. This drug should not be mixed with calcium-containing solutions or other intravenous medications, and must be administered only intravenously. After use, the injection needle and syringe should not be reused but disposed of safely. During the administration of this drug, serious allergic reactions such as anaphylaxis may occur. If symptoms appear, immediate cessation of administration and notification to medical staff is necessary.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • dyspepsia
  • nausea
  • constipation
  • musculoskeletal pain
  • arthralgia
  • myalgia
  • influenza-like illness
Show 27 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • urticaria
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • bullous dermatitis
  • atypical femoral fracture
  • subtrochanteric femoral fracture
  • external auditory canal osteonecrosis
  • acute renal failure
  • sensory loss

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be stored in a sealed container to prevent exposure to air or moisture and should be kept at room temperature, ideally between 1 and 30 degrees Celsius. Proper storage will help maintain the efficacy and safety of the medication.

Appearance and packaging

Appearance

A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, with a single-use injection needle attached.

Package unit

3mL × 1 vial

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.